Elicio Therapeutics On May 23 Announced Preliminary Data From Ongoing AMPLIFY-7P Phase 1a Study Of ELI-002 7P In Patients With mKRAS-Driven Solid Tumors At 2024 ASCO Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Elicio Therapeutics announced preliminary data from its ongoing AMPLIFY-7P Phase 1a study of ELI-002 7P in patients with mKRAS-driven solid tumors at the 2024 ASCO Annual Meeting. The study showed that ELI-002 7P was well tolerated and generated a significant mKRAS-specific T cell response in all patients, with notable tumor biomarker reductions and antigen-spreading effects.
May 24, 2024 | 4:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Elicio Therapeutics' ELI-002 7P demonstrated promising preliminary results in the AMPLIFY-7P Phase 1a study, showing a strong mKRAS-specific T cell response and significant tumor biomarker reductions in patients with mKRAS-driven solid tumors.
The positive preliminary data from the Phase 1a study of ELI-002 7P, including a strong mKRAS-specific T cell response and significant tumor biomarker reductions, is likely to boost investor confidence and positively impact Elicio Therapeutics' stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100